Early in Alzheimer’s disease, your brain can begin to change long before anyone notices a lost name or missed appointment.

Activating two somatostatin receptors enhances amyloid beta breakdown and improves memory in models of Alzheimer’s disease. Scientists at Karolinska Institutet in Sweden and the RIKEN Center for Brain ...

SciNeuro Pharmaceuticals has announced a global licensing and collaboration agreement with Novartis to develop SciNeuro’s ...

How can we influence whether we develop Alzheimer's disease later in life? Neurodegeneration researchers at the Institute for ...

Researchers have found that 40 Hz auditory stimulation may help clear the brain of amyloid plaques. Read on to ​discover more ...

Novartis has agreed to pay up to $1.7 billion to license an experimental Alzheimer’s therapy from China-based SciNeuro, a ...

ARIA is the most common side effect of anti–amyloid-beta MAB treatment. MABs increase vascular permeability, which can result in inflammation and leakage of proteinaceous fluid and blood products, ...

While amyloid β plaques are hallmarks of Alzheimer’s disease (AD), recent research suggests that they aren’t the only players in the neurodegenerative disorder. Genome-wide association studies and RNA ...

But cell and gene therapies (CGTs) are catching up. During Cell and Gene Therapy International Europe 2025, held in Berlin, ...